• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children

Video

Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.

Adolescents and young adults with acute lymphoblastic leukemia (ALL) tend to have worse outcomes than children with ALL, and new research published at the 59th American Society of Hematology Annual Meeting delved into the reasons why, explained Julie A. Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.

Transcript

How do outcomes of adolescents and young adults with acute lymphoblastic leukemia differ from children?

Adolescents and young adults, or AYAs, the National Cancer Institute defines as patients who are diagnosed with cancer between the ages of 15 and 39, and AYAs with ALL in specific have poor survival compared with children. So children, in our study, we had comparable survival to what's been shown nationally before, which is about 70% to 80%, depending on their age; in AYAs, it's more 35% to 45%, depending on the age, as well.

What are the reasons for the differences in outcomes between AYAs and children?

So that's a really important question, and it's something that we're really all trying to get to the bottom of. In our study, what we looked at was, in specific, in AYAs what predicted that poor survival. And there were 2 different times when they relapsed, and in terms of the risk of that relapse, we found that if they were going to relapse on therapy, there was about a 2.2-fold increased risk in patients on therapy if they were from non-white races or ethnicities. And there was a 2.6-fold increased risk of relapse if the were not enrolled on a clinical trial, as compared with patients that were enrolled on a clinical trial.

But then when we looked at the risk of relapse after they finished treatment, if was actually the duration of therapy. So for each additional month of maintenance treatment that they had, there was a 30% decreased risk of relapse. And for each additional month of consolidation treatment, there was a 20% decreased risk of relapse. There was also a trend toward association with socioeconomic status and insurance there.

Related Videos
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Alexander Mathioudakis, MD, PhD, clinical lecturer in respiratory medicine at The University of Manchester
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Surbhi Sidana, MD, MBBS
Screenshot of Susan Wescott, RPh, MBA
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.